Hman Lefaxin Family (Comparative 2025)
Three lefaxin genes in H. manillensis (Hman1/2/3) with stronger Factor Xa binding + anticoagulant activity than non-hematophagous comparators — Ye 2025.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Three lefaxin genes in H. manillensis (Hman1/2/3) with stronger Factor Xa binding + anticoagulant activity than non-hematophagous comparators — Ye 2025.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Comparative lefaxin anticoagulant assays in vitro do NOT establish clinical efficacy. No FDA-approved derivative; H. manillensis is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Hirudinaria manillensis
- Discovered
- 2025 · Ye T et al.
Biological Targets
- → coagulation Factor Xa
Key Citations
- Ye T et al. (2025), Biology (Basel) · PMID 40906077
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.